PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31983427-4	2020	Using patch-clamp electrophysiology, we show that Cdk5 inhibition by Olomoucine significantly increases current density through CaV1.3 (L-type) channels heterologously expressed in HEK293 cells.	olomoucine	69-79	cyclin dependent kinase 5	Homo sapiens	50-54	
9933594-8	1999	Inhibition of Cdk5 with olomoucine decreased evoked norepinephrine secretion from chromaffin cells, an effect not observed with the inactive analogue iso-olomoucine.	olomoucine	24-34	cyclin dependent kinase 5	Homo sapiens	14-18	
15033170-6	2004	Administration of Cdk5 inhibitors, roscovitine and olomoucine, into the crushed nerves resulted in decreases in Cdk5 kinase activity in nerves and retardation of nerve fiber regrowth.	olomoucine	51-61	cyclin dependent kinase 5	Homo sapiens	18-22	
21465480-8	2012	Decreased GTP-induced vimentin Ser56 phosphorylation and secretion resulted from inhibition of Cdk5 activity by roscovitine or olomoucine or by depletion of Cdk5 by siRNA, suggesting that GTP-induced Cdk5-mediated vimentin Ser56 phosphorylation may be related to GTP-induced Cdk5-mediated secretion by neutrophils.	olomoucine	127-137	cyclin dependent kinase 5	Homo sapiens	95-99	
18948252-2	2008	In turn, activated CDK5 phosphorylates the Rho family GTP-binding protein TC10alpha on threonine 197 that is sensitive to the CDK5 inhibitor olomoucine and blocked by small interfering RNA-mediated knockdown of CDK5.	olomoucine	141-151	cyclin dependent kinase 5	Homo sapiens	19-23	
18948252-2	2008	In turn, activated CDK5 phosphorylates the Rho family GTP-binding protein TC10alpha on threonine 197 that is sensitive to the CDK5 inhibitor olomoucine and blocked by small interfering RNA-mediated knockdown of CDK5.	olomoucine	141-151	cyclin dependent kinase 5	Homo sapiens	126-130	
18948252-2	2008	In turn, activated CDK5 phosphorylates the Rho family GTP-binding protein TC10alpha on threonine 197 that is sensitive to the CDK5 inhibitor olomoucine and blocked by small interfering RNA-mediated knockdown of CDK5.	olomoucine	141-151	cyclin dependent kinase 5	Homo sapiens	126-130	
16815303-3	2006	Intraventricular injections of olomoucine and U-0126 (CDK5 and MAP kinase inhibitors, respectively) inhibited hyperphosphorylation.	olomoucine	31-41	cyclin dependent kinase 5	Homo sapiens	54-58	
15033170-6	2004	Administration of Cdk5 inhibitors, roscovitine and olomoucine, into the crushed nerves resulted in decreases in Cdk5 kinase activity in nerves and retardation of nerve fiber regrowth.	olomoucine	51-61	cyclin dependent kinase 5	Homo sapiens	112-116	
10770290-7	2000	We show here that up-regulation of Cdk5 does not occur in granulocytic differentiation, whereas inhibition of Cdk5 activity by olomoucine, or its expression by a plasmid construct expressing antisense Cdk5, switches the 1,25D3-induced monocytic phenotype (a combination of positive nonspecific esterase reaction, expression of the CD14 marker, and morphology) to general myeloid phenotype (positive nitro-blue tetrazolium reaction, CD11b marker and morphology).	olomoucine	127-137	cyclin dependent kinase 5	Homo sapiens	110-114	
11743029-3	2001	Moreover, antisense oligonucleotide suppression of Cdk5 or p35 in young cultured neurons, as well as inhibition of Cdk5 activity with olomoucine, blocks the formation of membrane vesicles from the Golgi apparatus.	olomoucine	134-144	cyclin dependent kinase 5	Homo sapiens	115-119	
10770290-7	2000	We show here that up-regulation of Cdk5 does not occur in granulocytic differentiation, whereas inhibition of Cdk5 activity by olomoucine, or its expression by a plasmid construct expressing antisense Cdk5, switches the 1,25D3-induced monocytic phenotype (a combination of positive nonspecific esterase reaction, expression of the CD14 marker, and morphology) to general myeloid phenotype (positive nitro-blue tetrazolium reaction, CD11b marker and morphology).	olomoucine	127-137	cyclin dependent kinase 5	Homo sapiens	110-114